What's Hot
View all perspectives
Dr. John Cush RheumNow
3 years 6 months ago
How to Measure Success in Lupus? Dr. Kathryn Dao ( @KDAO2011 )
https://t.co/z8c8moIQCa
#EULAR2021
Dr. Rachel Tate uptoTate
3 years 6 months ago
PREVENT: SEC 150 mg showed durable improvement in nr-axSpA through 2 yrs, 438 pts. No new or unexpected safety signals. Poster #POS0900 #EULAR2021 @RheumNow https://t.co/NU1EO9zktn https://t.co/LP3hkZodhi
Aurelie Najm AurelieRheumo
3 years 6 months ago
JUNIPERA trial: open label Secukinumab in ERA and JPsA: 90.4% JIA ACR 30 and 69.9% JIA ACR 70 W12 and > time to flare W104, 72% risk of flare reduction SEC vs PBO (HR: 0.28 95CI: 0.13–0.63 P<0.001). No particular safety signal.
#LB0002 @Rheumnow #EULAR2021 https://t.co/PJ9NYi25UI
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 6 months ago
We need to look after #mentalhealth (MH) of #SLE patients.Dr Petri studied large US database. MH prevalence = 36%(SLE) and 29%(Nephritis;LN).LN with MH stayed 7.2 days longer in-patient vs without MH. Health cost/year⬆️in SLE+MH ($49,553 vs $26,064) #EULAR2021 #POS0304 @RheumNow https://t.co/wa7XmJxx9O
David Liew drdavidliew
3 years 6 months ago
Even when we go outright looking for COVID vaccine-related problems in rheum disease patients, we really don't find much.
Get your rheumatology patients vaccinated!
reassuring from @eular_org COVAX registry, thanks to all involved! @pedrommcmachado LB0002 #EULAR2021 @RheumNow https://t.co/mIBeglQ5KS
Dr. John Cush RheumNow
3 years 6 months ago
#EULAR2021 and EULAR IQ
Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021.
https://t.co/BkHjhOUqNU https://t.co/4JS1yGiJHg
Dr. John Cush RheumNow
3 years 6 months ago
Sex Differences in Autoimmune Disease Susceptibility: Drs. Yusof and Robinson
Dr. Yusof interviews Dr. Robinson about abstract OP0013 presented at the virtual #EULAR2021 meeting.
https://t.co/IPe6lMM7NQ https://t.co/Dt36N3OhZg
Dr. John Cush RheumNow
3 years 6 months ago
RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, & Janssen. All content chosen by RheumNow & its Faculty.
Aurelie Najm AurelieRheumo
3 years 6 months ago
DANBIO + Swedish register SGR linked to national birth registers (matched 1:10): RA-pregnancies: higher preterm birth (OR 1.92, 95CI 1.56-2.35) and small gestational age (OR 1.93, 95CI 1.45-2.57). Association strengthened by high disease activity.
#OP0210 @Rheumnow #EULAR2021 https://t.co/Fjm0uxCPgC
Aurelie Najm AurelieRheumo
3 years 6 months ago
KEEPsAKE 2: Risankizumab RCT in Bio-IR or csDMARD-IR active PsA. Primary endpoint ACR20 W24 met with 51.3% vs 26.5% in PBO group (P < .001) and ACR50 26.3% vs 9.3%. No particular safety signal.
#OP0228 @Rheumnow #EULAR2021 https://t.co/HZv8qoc4sz
Aurelie Najm AurelieRheumo
3 years 6 months ago
What is the impact of RA on fertility in men:
#OP0211 and #OP0212 @Rheumnow #EULAR2021
Aurelie Najm AurelieRheumo
3 years 6 months ago
COSMOS study: Guselkumab RCT in PsA pts TNFi-resistants (1 or 2) 44.4% of GUS vs 19.8% of PBO pts achieved ACR20 at w24 (p<0.001) and GUS > PBO for most secondary endpoints. Tolerance: 18% vs. 20% infections/SI.
#OP0230 @Rheumnow #EULAR2021 @DrLauraCoates https://t.co/fFle2OR8KM
Aurelie Najm AurelieRheumo
3 years 6 months ago
Retrospective RA cohort study: overall risk of dementia ⬆️ in RA (HR 1.38; 95%CI 1.04-1.83) BUT 10-year cumulative incidence of dementia ⬇️:
12.7% in 1980s
7.2% in 1990s
2000s 6.2% Risk no longer significantly ⬆️ for patients w/ RA onset in 2000s! @RheumNow #EULAR2021 #OP0216 https://t.co/TVRTTJjvno
Poster Hall